Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism CVRM, BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
Department of Chemistry and Molecular Biology, University of Gothenburg, 41296 Gothenburg, Sweden.
Anal Chem. 2022 Jul 26;94(29):10549-10556. doi: 10.1021/acs.analchem.2c02111. Epub 2022 Jul 13.
Antisense oligonucleotide (ASO)-based therapeutics hold great potential for the treatment of a variety of diseases. Therefore, a better understanding of cellular delivery, uptake, and trafficking mechanisms of ASOs is highly important for early-stage drug discovery. In particular, understanding the biodistribution and quantifying the abundance of ASOs at the subcellular level are needed to fully characterize their activity. Here, we used a combination of electron microscopy and NanoSIMS to assess the subcellular concentrations of a S-labeled GalNAc-ASO and a naked ASO in the organelles of primary human hepatocytes. We first cross-validated the method by including a I-labeled ASO, finding that the absolute concentration of the lysosomal ASO using two independent labeling strategies gave matching results, demonstrating the strength of our approach. This work also describes the preparation of external standards for absolute quantification by NanoSIMS. For both the S and I approaches used for our quantification methodology, we established the limit of detection (5 and 2 μM, respectively) and the lower limit of quantification (14 and 5 μM, respectively).
反义寡核苷酸 (ASO) 类药物在治疗多种疾病方面具有巨大潜力。因此,更好地了解 ASO 的细胞内传递、摄取和运输机制对于早期药物发现非常重要。特别是,为了充分表征其活性,需要了解生物分布并定量亚细胞水平上 ASO 的丰度。在这里,我们使用电子显微镜和 NanoSIMS 的组合来评估 S 标记的 GalNAc-ASO 和裸 ASO 在原代人肝细胞细胞器中的亚细胞浓度。我们首先通过包含 I 标记的 ASO 来交叉验证该方法,发现使用两种独立的标记策略得到的溶酶体 ASO 的绝对浓度结果相匹配,证明了我们方法的优势。这项工作还描述了通过 NanoSIMS 进行绝对定量的外部标准品的制备。对于我们定量方法中使用的 S 和 I 两种方法,我们分别确定了检测限(5 和 2 μM)和定量下限(14 和 5 μM)。